Pegvisomant
Clinical data | |
---|---|
Trade names | Somavert |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Subcutaneous | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C990H1532N262O300S7 |
Molar mass | 22129.10 g·mol−1 |
(what is this?) (verify) |
Pegvisomant, sold under the brand name Somavert, is a
Medical uses
Pegvisomant is
Side effects
Side effects of pegvisomant include reactions at the injection site, swelling of the limbs, chest pain, hypoglycemia, nausea and hepatitis.[6]
Discovery
Pegvisomant was discovered at Ohio University in 1987 by Distinguished Professor
Structure
Pegvisomant is a protein containing 191 amino acid residues to which several polyethylene glycol polymers have been covalently bound in order to slow clearance from the blood.[5] The protein is a modified version of human growth hormone designed to bind to and block the growth hormone receptor. It is manufactured using genetically modified E. coli bacteria.[5]
Mechanism of action
Pegvisomant blocks the action of growth hormone on the growth hormone receptor to reduce the production of IGF-1.[8][9] IGF-1 is responsible for most of the symptoms of acromegaly, and the normalization of its levels can control the symptoms.[10]
Long-term treatment studies with pegvisomant as a monotherapy have shown it to be safe,[4] and effective.[11]
Research
Some studies show the potential of using pegvisomant as an anti-tumor treatment for certain types of cancers.[12][13]
References
- ^ a b c "Somavert- pegvisomant kit". DailyMed. 18 November 2021. Retrieved 18 May 2022.
- ^ a b c "Somavert EPAR". European Medicines Agency. 17 September 2018. Retrieved 18 May 2022.
- S2CID 12121175.
- ^ PMID 25370326.
- ^ a b c Scientific Discussion of Somavert (PDF) (Report). European Medicines Agency. 2004. Archived from the original (PDF) on 18 June 2018. Retrieved 17 February 2011.
- PMID 16728538.
- ^ "Ohio University, inventors to receive up to $52 million from drug license transactions". Ohio University. 15 February 2011. Archived from the original on 22 November 2016. Retrieved 21 November 2016.
- PMID 12670297.
- PMID 18058724.
- ^ CEDAC Final REcommendation on Reconsideration and Reasons for Recommendation: Pegvisomant (Somavert - Pfizer Canada Inc.) (PDF) (Report). Canadian Agency for Drugs and Technologies in Health. 2 August 2006. Archived from the original (PDF) on 28 June 2021. Retrieved 22 December 2014.
- S2CID 19588354.
- PMID 27241667.
- S2CID 6234700.
External links
- "Pegvisomant". Drug Information Portal. U.S. National Library of Medicine.